Climb Bio (NASDAQ:CLYM) used an investor R&D spotlight event to outline its strategy around CD19-targeted B-cell depletion ...

Management assumes sustained revenue growth for the balance of the year, noting that some Q1 shipments will be recognized in ...

Nonperfusion area detected by swept-source optical coherence tomography angiography (OCTA) may predict diabetic nephropathy (DN) severity, according to a stud ...

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued developmentBudoprutug pMN, ...

While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on ...

Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.47 per share for the first quarter of 2026, beating the Zacks ...

Vertex stock skidded Tuesday on a mixed first-quarter report, but analysts remain more interested in the company's R&D plans.

GFR slope predicts kidney outcomes in IgA nephropathy beyond static measures. Learn how this could refine trials and risk ...

AstraZeneca (AZN) announced plans to seek accelerated approval for its rare disease therapy, Ultomiris, on Tuesday after the C5 complement inhibitor reached a key goal in a late-stage trial for ...

Drug discovery still too often relies on expensive trial and error. Researchers from ICTER show there is another way—building ...

Positive high-level results from a prespecified interim analysis of the I CAN Phase III trial showed that Ultomiris (ravulizumab) met its primary ...

Researchers have found in a new study that Intraperitoneal (IP) therapy demonstrated better efficacy than MSII in improving ...